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研究 FA-PEG 修饰的壳聚糖载药纳米粒子在大鼠体内的动态代谢特征。 
论文研究结果：（1）利用双交联法成功制备出粒径可控在 200~500nm，性能
稳定的壳聚糖纳米粒子。（2）经 FA 和 PEG 共同修饰，并载有丝裂霉素的壳聚糖
纳米粒子，其载药量为 9.73%、包封率为 21.58%，体外释药行为呈现速释和缓















表明：FA 修饰能增加粒子被 HeLa 细胞摄取的能力。而体内抑瘤率试验结果显
示：载药纳米粒子与原料药的抑瘤率相似，达到 31.4%，但是 FA-PEG 修饰的载
药纳米粒子能显著降低药物的全身毒副作用。（4）药代动力学试验结果显示：
FA-PEG 修饰的壳聚糖载药纳米粒子的药-时曲线下面积（AUC）、表观分布容积
（Vd）和半衰期（t1/2）均大于 MMC 注射剂，而且其总清除率（CL）小于 MMC




















Presently, cancer has become one of the most serious diseases which endanger 
human health. Chemotherapy is often impotent in effectible treatment due to 
unfavorable specificity towards tumors and great side effects and brings great pain to 
the patients.As a result, the all-important challenge for researchers is to ameliorate the 
quality of patient’s life and improve the specificity and safety of anti-cancer 
drugs.The binding between folate-acid (FA) and its receptor is specific and selective. 
Based on the fact that folate receptor can be over-expressed on the surface of some 
kinds of tumor cells but scarcely expressed on normal cells, the delivery system 
modified folate-acid to achieve targeted therapy has drawn great attention by 
researchers.Chitosan with good biocompatibility and biodegradability is a common 
carrier material of nano drug delivery system, which has caused widespread concern 
for its characteristic of controlled release of drug. In addition, polyethylene glycol 
(PEG), a hydrophilic polymer, can modify the drug delivery system to increase the 
circulation time. The present study aims to develop a stable, size controllable 
nanoparticle, and make it become a safe, long cycle, tumor-targeting drug delivery 
system after carrying drugs and modifying with FA and PEG. 
The present work includes: (1) Double-cross-linking method, combination of 
ionic crosslinking and chemical crosslinking, was developed to prepare chitosan 
nanoparticles with controlled size and good stability.  The influences of the mass 
ratio of Sodium polyphosphate (STPP) and chitosan, reaction time and pH of chitosan 
on the particle size were investigated. The effect of quantity of glutaraldehyde on the 
morphology of the nanoparticles and the number of amino groups on the surface has 
been researched; (2) Through grafting PEG modified by activated folic acid on the 
surface of nanoparticles, it has the characteristics of active targeting and long 
circulating. The structures of modified PEG, activated folic acid and nanoparticals 














mitomycin C (MMC) loading nanoparticals; (3) Cytotoxicity test, laser scanning 
confocal imaging and in vivo antitumor effect in hepatoma-22 bearing mice were 
performed to study the behavior of the drug system; (4) Metabolic behavior of 
chitosan nanoparticles modified by FA-PEG was investigated by pharmacokinetic 
experiment in rats. 
The main findings are as follows:(1) Successful synthesis of an size around 
200~500nm and stable chitosan nanocarriers by double-cross-linked method; (2)The 
folate acid and polyethylene glycol modified MMC-loading nanoparticles which 
drug-loading and entrapment efficiency respectively were 9.73% and 21.58% were 
prepared. Their release behavior in vitro showed biphasic characteristics of burst 
releasing and sustained releasing; (3) It’s shown by Cytotoxicity test, that chitosan 
nanoparticles modified by FA-PEG is the higher cytotoxic which higher as time 
increases. Confocal laser experiment also proved that particles modified by folate acid 
could increase the uptake by HeLa cells. The antitumor test showed that the 
therapeutic effect of MMC-FA-PEG-modified nanoparticles was 31.4% which was 
similar to MMC. Meanwhile, they can significantly reduce the systemic toxicity of 
drugs; (4) Pharmacokinetic parameter displayed that the AUC、Vd and t1/2 of MMC 
were increased and CL of it was decreased by grafted on the surface of 
FA-PEG-nanoparticles. In conclusion, the MMC-FA-PEG-modified nanoparticles 
have the properties of controlled- release and long circulation. 
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于 小有效浓度，则影响疗效；②给药次数常达 3-4 次/d，给药不方便；③治疗
指数小，消除半衰期短的药物频繁给药导致蓄积中毒等；④受胃肠道生理因素影




















































1.3 纳米载药系统  
1.3.1 纳米给药系统的定义 











































































































































































图 1.1 聚乳酸的合成 






























图 1.2 PLGA 的合成 





















LA∶GA 为 9∶l 的 PLGA 材料，将左旋 18-甲基炔诺酮(LNG)与其共混制成
LNG-PLGA 微球，对大鼠肌肉注射给药，观察 196 d 的血药浓度，在 100 d 内有
相当平稳的血药水平。Singh[16]用 PLGA(85∶15)与炔诺酮(NET)共混制得微球，
其 NET 的含量为 25%～56%，60 mg 的高聚物药物注入人体内后，在 90 d 内 NET










图 1.3 PCL 的合成 
Fig.1.3 Synthesis of PCL 
 
PCL 是线性的脂肪聚酯，为半结晶态聚合物，结晶度约为 45%左右。PCL
具有其它聚酯所不具备的特性，即超低的玻璃态转变温度（Tg = -62 °C）和低熔
点（Tm = 57 °C），在室温下呈橡胶态，这可能是 PCL 比其它聚酯有更好的药物
通透性的原因，并且具有很好的热稳定性。聚己内酯(PCL)是具有良好药物通透
性能的高分子材料，在医学领域已经有广泛的应用，所以对 PCL 的研究也很多。
Pitt 和 Schindler 早在 20 世纪 70 年代就提出 PCL 可用作药物控释载体，并对其
药物通过性和生物降解性进行了系统研究。宋存先等[17]研究了 PCL 在大鼠体内
的降解情况，发现 PCL 的降解分两个阶段进行：第一个阶段为分子量不断下降
但不发生形变和失重，起始分子量 6.6 万的 PCL 在体内可以完整保存 2 年；第二












































的浓集，因此从靶向性和控释性上看都是有利的[20]。   
（3）海藻酸钠 又称海藻胶、褐藻酸钠或海带胶，是从褐藻类的海带或马尾
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